New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
13:25 EDTILMN, ILMN, ILMN, LMNX, LMNX, LMNX, CPHD, CPHD, CPHD, GNMK, GNMK, GNMK, NSTG, NSTG, NSTG, MYGN, MYGN, MYGN, FLDM, FLDM, FLDM, PACB, PACB, PACB, TMO, TMO, TMO, QGEN, QGEN, QGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
News For ILMN;TMO;PACB;FLDM;MYGN;NSTG;GNMK;CPHD;LMNX;QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
10:01 EDTCPHDOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:21 EDTQGENQIAGEN downgraded to Sell from Neutral at Goldman
Goldman downgraded QIAGEN to Sell based on a mixed growth outlook for new products and the dilutive impact on the core franchise value from M&A. Price target lowered to $19 from $21.
06:07 EDTCPHDCepheid upgraded to Buy from Neutral at BofA/Merrill
December 17, 2014
10:21 EDTMYGNMyriad denied appeal to block competing breast cancer tests, Bloombeg reports
Subscribe for More Information
10:02 EDTTMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
December 16, 2014
16:16 EDTTMOThermo Fisher initiated with a Buy at KeyBanc
Subscribe for More Information
December 11, 2014
12:54 EDTMYGNMyriad Genetics management to meet with William Blair
Subscribe for More Information
December 8, 2014
16:07 EDTNSTGNanoString updates Prosigna FDA labeling
NanoString Technologies announced that the FDA has cleared a labeling update for the Prosigna Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8, or ABCSG-8, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive, or ER+, early-stage breast cancer.
07:26 EDTFLDM, CPHDLeerink to hold a tour
Subscribe for More Information
December 5, 2014
05:55 EDTCPHDCDC data postiive for flu testing companies, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use